{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:00:29Z","timestamp":1787061629297,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,11]]},"DOI":"10.7759\/cureus.69146","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T03:53:24Z","timestamp":1726026804000},"source":"Crossref","is-referenced-by-count":4,"title":["Cefotaxime Versus Ceftriaxone: A Comprehensive Comparative Review"],"prefix":"10.7759","author":[{"given":"Birendra","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghuvendra","family":"Chalikwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Bhalerao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajitkumar A","family":"Gondane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dattatray","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins","volume":"17","author":"Kalman D","year":"1990","unstructured":"Kalman D, Barriere SL. Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. Tex Heart Inst J. 1990, 17:203-15.","journal-title":"Tex Heart Inst J"},{"key":"ref2","article-title":"Cefotaxime: microbiology, pharmacology, and clinical use","volume":"1","author":"Dudley MN","year":"1982","unstructured":"Dudley MN, Barriere SL. Cefotaxime: microbiology, pharmacology, and clinical use. Clin Pharm. 1982, 1:114-24.","journal-title":"Clin Pharm"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040040-00008","article-title":"Cefotaxime. An update of its pharmacology and therapeutic use","volume":"40","author":"Todd PA","year":"1990","unstructured":"Todd PA, Brogden RN. Cefotaxime. An update of its pharmacology and therapeutic use. Drugs. 1990, 40:608-51. 10.2165\/00003495-199040040-00008","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198325030-00001","article-title":"Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use","volume":"25","author":"Carmine AA","year":"1983","unstructured":"Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1983, 25:223-89. 10.2165\/00003495-198325030-00001","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199813010-00009","article-title":"Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections","volume":"13","author":"Plosker GL","year":"1998","unstructured":"Plosker GL, Foster RH, Benfield P. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections. Pharmacoeconomics. 1998, 13:91-106. 10.2165\/00019053-199813010-00009","journal-title":"Pharmacoeconomics"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753030-00009","article-title":"Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections","volume":"53","author":"Brogden RN","year":"1997","unstructured":"Brogden RN, Spencer CM. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections. Drugs. 1997, 53:483-510. 10.2165\/00003495-199753030-00009","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.165564","article-title":"Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America","volume":"111","author":"Baddour LM","year":"2005","unstructured":"Baddour LM, Wilson WR, Bayer AS, et al.. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005, 111:e394-434. 10.1161\/CIRCULATIONAHA.105.165564","journal-title":"Circulation"},{"key":"ref8","article-title":"Cephalosporins","author":"Bui T","year":"2023","unstructured":"Bui T, Preuss CV. Cephalosporins. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref9","article-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically","year":"2018","unstructured":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Clinical and Laboratory Standards Institute, Wayne, PA; 2018."},{"key":"ref10","article-title":"Ceftriaxone-Contraindication in Newborns and Risk of Calcium Ceftriaxone Precipitation When Administered\/Mixed With Solution Containing Calcium","year":"2010","unstructured":"Ceftriaxone-Contraindication in Newborns and Risk of Calcium Ceftriaxone Precipitation When Administered\/Mixed With Solution Containing Calcium. New Clinical. 2010, xiv.","journal-title":"New Clinical"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v62i2.447","article-title":"Notice to hospitals regarding ceftriaxone-calcium incompatibility: what's a clinician to do?","volume":"62","author":"Gin A","year":"2009","unstructured":"Gin A, Walker S. Notice to hospitals regarding ceftriaxone-calcium incompatibility: what's a clinician to do?. Can J Hosp Pharm. 2009, 62:157-8. 10.4212\/cjhp.v62i2.447","journal-title":"Can J Hosp Pharm"},{"key":"ref12","article-title":"Performance Standards Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement","year":"2013","unstructured":"Performance Standards Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. Clinical and Laboratory Standards Institute, Wayne, PA; 2013."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198427060-00001","article-title":"Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use","volume":"27","author":"Richards DM","year":"1984","unstructured":"Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984, 27:469-527. 10.2165\/00003495-198427060-00001","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/4.supplement_2.s300","article-title":"Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity","volume":"4 Suppl","author":"Jones RN","year":"1982","unstructured":"Jones RN, Thornsberry C. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. Rev Infect Dis. 1982, 4 Suppl:S300-15. 10.1093\/clinids\/4.supplement_2.s300","journal-title":"Rev Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/9.4.713","article-title":"Does serum protein binding inhibit tissue penetration of antibiotics?","volume":"9","author":"Bergan T","year":"1987","unstructured":"Bergan T, Engeset A, Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics?. Rev Infect Dis. 1987, 9:713-8. 10.1093\/clinids\/9.4.713","journal-title":"Rev Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128%2Faac.31.5.818","article-title":"Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, cefotaxime - desacetylcefotaxime in the presence of human serum","volume":"31","author":"Jones RN","year":"1987","unstructured":"Jones RN, Barry AL. Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, cefotaxime - desacetylcefotaxime in the presence of human serum. Antimicrob Agents Chemother. 1987, 31:818-20. 10.1128%2Faac.31.5.818","journal-title":"Antimicrob Agents Chemother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1378\/chest.96.6.1292","article-title":"Comparison of ceftriaxone with cefotaxime in serious chest infections","volume":"96","author":"Reeves JH","year":"1989","unstructured":"Reeves JH, Russell GM, Cade JF, McDonald M. Comparison of ceftriaxone with cefotaxime in serious chest infections. Chest. 1989, 96:1292-7. 10.1378\/chest.96.6.1292","journal-title":"Chest"},{"key":"ref18","article-title":"Ceftriaxone in intensive care units (chap 31)","author":"Mouton Y","year":"1986","unstructured":"Mouton Y, Beuscart C, Deboscker Y, et al.. Ceftriaxone in intensive care units (chap 31). Changing Concepts in Management of Serious Infections (Poster Book). Roche, Basel, Switzerland; 1986."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.101.5.1393","article-title":"Efficacy of a low dose of cefotaxime in serious chest infections","volume":"101","author":"Cade JF","year":"1992","unstructured":"Cade JF, Presneill J, Keighley C, Sinickas V. Efficacy of a low dose of cefotaxime in serious chest infections. Chest. 1992, 101:1393-8. 10.1378\/chest.101.5.1393","journal-title":"Chest"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(95)00083-m","article-title":"Cefotaxime versus ceftriaxone for the treatment of nosocomial pneumonia. Results of a multicenter study","volume":"22","author":"Shah PM","year":"1995","unstructured":"Shah PM, Stille W. Cefotaxime versus ceftriaxone for the treatment of nosocomial pneumonia. Results of a multicenter study. Diagn Microbiol Infect Dis. 1995, 22:171-2. 10.1016\/0732-8893(95)00083-m","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref21","article-title":"Claforan [Package Insert]","year":"2015","unstructured":"Claforan [Package Insert]. Sanofi-Aventis U.S. LLC, Bridgewater, NJ; 2015."},{"key":"ref22","article-title":"Rocephin [package insert]","year":"2018","unstructured":"Rocephin [package insert]. Genentech USA, Inc, San Francisco, CA; 2018."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36078","article-title":"An in vitro susceptibility study of cefotaxime-sulbactam on clinical bacterial isolates from various regions in india: a comparison with ceftriaxone-sulbactam","volume":"15","author":"Gondane AA","year":"2023","unstructured":"Gondane AA, Pawar DB. An in vitro susceptibility study of cefotaxime-sulbactam on clinical bacterial isolates from various regions in india: a comparison with ceftriaxone-sulbactam. Cureus. 2023, 15:e36078. 10.7759\/cureus.36078","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1772564","article-title":"Activity of cefotaxime versus ceftriaxone against pathogens isolated from various systemic infections: a prospective, multicenter, comparative, in vitro Indian study","volume":"15","author":"Gondane AA","year":"2023","unstructured":"Gondane AA, Pawar DB. Activity of cefotaxime versus ceftriaxone against pathogens isolated from various systemic infections: a prospective, multicenter, comparative, in vitro Indian study. J Lab Physicians. 2023, 15:10.1055\/s-0043-1772564","journal-title":"J Lab Physicians"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(92)90062-x","article-title":"Comparison of the efficacy and adverse effect profile of cefotaxime and ceftriaxone in ICU patients with susceptible infections","volume":"15","author":"Thomas P","year":"1992","unstructured":"Thomas P, Daly S, Misan G, Steele T. Comparison of the efficacy and adverse effect profile of cefotaxime and ceftriaxone in ICU patients with susceptible infections. Diagn Microbiol Infect Dis. 1992, 15:89-97. 10.1016\/0732-8893(92)90062-x","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/160.3.442","article-title":"Ceftriaxone compared with cefotaxime for serious bacterial infections","volume":"160","author":"Smith CR","year":"1989","unstructured":"Smith CR, Petty BG, Hendrix CW, et al.. Ceftriaxone compared with cefotaxime for serious bacterial infections. J Infect Dis. 1989, 160:442-7. 10.1093\/infdis\/160.3.442","journal-title":"J Infect Dis"},{"key":"ref27","article-title":"Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism","volume":"2","author":"Chin NX","year":"1984","unstructured":"Chin NX, Neu HC. Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism. Diagn Microbiol Infect Dis. 1984, 2:21S-31S.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.3823\/839","article-title":"Cefotaxime vs ceftriaxone for the prolongation of latency period in preterm premature rupture of membranes","volume":"10","author":"Rasti SD","year":"2020","unstructured":"Rasti SD, Rochmanti M, Primariawan RY. Cefotaxime vs ceftriaxone for the prolongation of latency period in preterm premature rupture of membranes. Int Arab J Antimicrob Agents. 2020, 10:1-9.","journal-title":"Int Arab J Antimicrob Agents"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.22038\/ijp.2017.26241.2244","article-title":"Clinical pharmacology of cefotaxime in neonates and infants: effects and pharmacokinetics","volume":"5","author":"Pacifici G","year":"2017","unstructured":"Pacifici G, Marchini G. Clinical pharmacology of cefotaxime in neonates and infants: effects and pharmacokinetics. Int J Paediatr. 2017, 5:6111-38. 10.22038\/ijp.2017.26241.2244","journal-title":"Int J Paediatr"},{"key":"ref30","article-title":"Experience with cefotaxime in gynecology and obstetrics","volume":"4","author":"Takase Z","year":"1981","unstructured":"Takase Z. Experience with cefotaxime in gynecology and obstetrics. Clin Ther. 1981, 4:25-44.","journal-title":"Clin Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/4.supplement_2.s432","article-title":"Clinical experience with cefotaxime in obstetric and gynecologic infections","volume":"4","author":"Hemsell DL","year":"1982","unstructured":"Hemsell DL, Cunningham FG, Nolan CM, Miller TT. Clinical experience with cefotaxime in obstetric and gynecologic infections. Rev Infect Dis. 1982, 4:S432-8. 10.1093\/clinids\/4.supplement_2.s432","journal-title":"Rev Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90677-d","article-title":"Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis: a randomized controlled study of 100 patients","volume":"100","author":"Runyon BA","year":"1991","unstructured":"Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis: a randomized controlled study of 100 patients. Gastroenterol. 1991, 100:1737-42. 10.1016\/0016-5085(91)90677-d","journal-title":"Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2014\/9742.5090","article-title":"Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study","volume":"8","author":"Kaur K","year":"2014","unstructured":"Kaur K, Gupta A, Sharma A, Walia G, Singh B, Kaur K. Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study. J Clin Diagn Res. 2014, 8:HC05-8. 10.7860\/JCDR\/2014\/9742.5090","journal-title":"J Clin Diagn Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3748%2Fwjg.v11.i43.6823","article-title":"Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotic","volume":"11","author":"Chen TA","year":"2005","unstructured":"Chen TA, Lo GH, Lai KH, et al.. Single daily amikacin versus cefotaxime in the short-course treatment of spontaneous bacterial peritonitis in cirrhotic. World J Gastroenterol. 2005, 11:6823-8. 10.3748%2Fwjg.v11.i43.6823","journal-title":"World J Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/48.4.527","article-title":"Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial","volume":"48","author":"Cordero E","year":"2001","unstructured":"Cordero E, Bouza E, Ruiz I, Pachon J. Cefepime versus cefotaxime for empirical treatment of bacterial pneumonia in HIV-infected patients: an open, randomized trial. J Antimicrob Chemother. 2001, 48:527-34. 10.1093\/jac\/48.4.527","journal-title":"J Antimicrob Chemother"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/4.supplement_2.s421","article-title":"Clinical trials of cefotaxime for the treatment of bacterial infections of the lower respiratory tract","volume":"4","author":"Perkins RL","year":"1982","unstructured":"Perkins RL. Clinical trials of cefotaxime for the treatment of bacterial infections of the lower respiratory tract. Rev Infect Dis. 1982, 4:S421-31. 10.1093\/clinids\/4.supplement_2.s421","journal-title":"Rev Infect Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20174030","article-title":"Single dose antibiotic prophylaxis in elective obstetric and gynaecological surgeries-a descriptive study","volume":"6","author":"Mohan J","year":"2017","unstructured":"Mohan J, Thangaroja T, Menon M. Single dose antibiotic prophylaxis in elective obstetric and gynaecological surgeries-a descriptive study. Int J Reprod Contracept Obstet Gynecol. 2017, 6:3897-903. 10.18203\/2320-1770.ijrcog20174030","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01429-08","article-title":"Evaluation of cefotaxime and desacetylcefotaxime concentrations in cord blood after intrapartum prophylaxis with cefotaxime","volume":"53","author":"Lepercq J","year":"2009","unstructured":"Lepercq J, Treluyer JM, Auger C, Raymond J, Rey E, Schmitz T, Jullien V. Evaluation of cefotaxime and desacetylcefotaxime concentrations in cord blood after intrapartum prophylaxis with cefotaxime. Antimicrob Agents Chemother. 2009, 53:2342-5. 10.1128\/AAC.01429-08","journal-title":"Antimicrob Agents Chemother"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020230","article-title":"Antimicrobial prophylaxis reduces the rate of surgical site infection in upper gastrointestinal surgery: a systematic review","volume":"11","author":"Marano L","year":"2022","unstructured":"Marano L, Carbone L, Poto GE, et al.. Antimicrobial prophylaxis reduces the rate of surgical site infection in upper gastrointestinal surgery: a systematic review. Antibiotics (Basel). 2022, 11:10.3390\/antibiotics11020230","journal-title":"Antibiotics (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-43891-2_3","article-title":"Surgical site infections and antibiotic prophylaxis in surgery","author":"De Gasperi A","year":"2024","unstructured":"De Gasperi A, Merli M, Petr\u00f2 L, Roselli E. Surgical site infections and antibiotic prophylaxis in surgery. Practical Trends in Anesthesia and Intensive Care. Chiumello D (ed): Springer, Cham; 2024. 10.1007\/978-3-031-43891-2_3"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1155\/1995\/617610","article-title":"Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin","volume":"6","author":"Nath SK","year":"1995","unstructured":"Nath SK, Foster GA, Mandell LA, Rotstein C. Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin. Can J Infect Dis. 1995, 6:21-7. 10.1155\/1995\/617610","journal-title":"Can J Infect Dis"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02244-18","article-title":"Ceftriaxone and cefotaxime have similar effects on the intestinal microbiota in human volunteers treated by standard-dose regimens","volume":"63","author":"Burdet C","year":"2019","unstructured":"Burdet C, Grall N, Linard M, et al.. Ceftriaxone and cefotaxime have similar effects on the intestinal microbiota in human volunteers treated by standard-dose regimens. Antimicrob Agents Chemother. 2019, 63:10.1128\/AAC.02244-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10071-23148","article-title":"Antimicrobial agents-induced hypokalemia: a possible causality association","volume":"23","author":"Singh Rehan H","year":"2019","unstructured":"Singh Rehan H, Hotha P. Antimicrobial agents-induced hypokalemia: a possible causality association. Indian J Crit Care Med. 2019, 23:175-7. 10.5005\/jp-journals-10071-23148","journal-title":"Indian J Crit Care Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07925-y","article-title":"Haematological and hepatic adverse effects of ceftriaxone in ambulatory care: a dual-centre retrospective observational analysis of standard vs high dose","volume":"22","author":"Mistry R","year":"2022","unstructured":"Mistry R, Rawson TM, Troise O, Mughal N, Moore LS, Hughes S. Haematological and hepatic adverse effects of ceftriaxone in ambulatory care: a dual-centre retrospective observational analysis of standard vs high dose. BMC Infect Dis. 2022, 22:959. 10.1186\/s12879-022-07925-y","journal-title":"BMC Infect Dis"},{"key":"ref45","article-title":"A case report on ceftriaxone-induced periorbital edema","volume":"14","author":"Mathew B","year":"2021","unstructured":"Mathew B, Thomas S, Kumar S, et al.. A case report on ceftriaxone-induced periorbital edema. Indian J Pharm Pract. 2021, 14:","journal-title":"Indian J Pharm Pract"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.5799\/jcei\/5760","article-title":"Ceftriaxone-induced unilateral facial angioedema","volume":"10","author":"Alanli R","year":"2019","unstructured":"Alanli R. Ceftriaxone-induced unilateral facial angioedema. J Clin Exp Investig. 2019, 10:10.5799\/jcei\/5760","journal-title":"J Clin Exp Investig"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.22159\/ajpcr.2019.v12i1.25293","article-title":"Ceftriaxone-induced periorbital edema","volume":"12","author":"Nayak V","year":"2019","unstructured":"Nayak V, Somu K, Thomson SR, et al.. Ceftriaxone-induced periorbital edema. Asian J Pharm Clin Res. 2019, 12:7-8. 10.22159\/ajpcr.2019.v12i1.25293","journal-title":"Asian J Pharm Clin Res"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw385","article-title":"Role of cephalosporins in the era of Clostridium difficile infection","volume":"72","author":"Wilcox MH","year":"2017","unstructured":"Wilcox MH, Chalmers JD, Nord CE, Freeman J, Bouza E. Role of cephalosporins in the era of Clostridium difficile infection. J Antimicrob Chemother. 2017, 72:1-18. 10.1093\/jac\/dkw385","journal-title":"J Antimicrob Chemother"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt107","article-title":"Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model","volume":"68","author":"Baines SD","year":"2013","unstructured":"Baines SD, Chilton CH, Crowther GS, Todhunter SL, Freeman J, Wilcox MH. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. J Antimicrob Chemother. 2013, 68:1842-9. 10.1093\/jac\/dkt107","journal-title":"J Antimicrob Chemother"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa312","article-title":"Switching from ceftriaxone to cefotaxime significantly contributes to reducing the burden of Clostridioides difficile infections","volume":"7","author":"Wendt S","year":"2020","unstructured":"Wendt S, Ranft D, Rodloff AC, Lippmann N, L\u00fcbbert C. Switching from ceftriaxone to cefotaxime significantly contributes to reducing the burden of Clostridioides difficile infections. Open Forum Infect Dis. 2020, 7:ofaa312. 10.1093\/ofid\/ofaa312","journal-title":"Open Forum Infect Dis"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/132452","article-title":"Acute cholecystitis caused by ceftriaxone stones in an adult","volume":"2009","author":"Becker CD","year":"2009","unstructured":"Becker CD, Fischer RA. Acute cholecystitis caused by ceftriaxone stones in an adult. Case Rep Med. 2009, 2009:132452. 10.1155\/2009\/132452","journal-title":"Case Rep Med"},{"key":"ref52","article-title":"Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy","volume":"21","author":"Guggenbichler JP","year":"1986","unstructured":"Guggenbichler JP, Allerberger FJ, Dierich M. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatr Padol. 1986, 21:335-42.","journal-title":"Padiatr Padol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198507000-00006","article-title":"Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children","volume":"4","author":"Barson WJ","year":"1985","unstructured":"Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children. Pediatr Infect Dis. 1985, 4:362-8. 10.1097\/00006454-198507000-00006","journal-title":"Pediatr Infect Dis"},{"key":"ref54","article-title":"Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia","volume":"77","author":"Baumgartner JD","year":"1984","unstructured":"Baumgartner JD, Glauser MP. Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia. Am J Med. 1984, 77:54-8.","journal-title":"Am J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199001183220301","article-title":"A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children","volume":"322","author":"Schaad UB","year":"1990","unstructured":"Schaad UB, Suter S, Gianella-Borradori A, et al.. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med. 1990, 322:141-7. 10.1056\/NEJM199001183220301","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.4174\/jkss.2011.81.6.423","article-title":"Gallbladder pseudolithiasis caused by ceftriaxone in young adult","volume":"81","author":"Choi YY","year":"2011","unstructured":"Choi YY, Jung YH, Choi SM, Lee CS, Kim D, Hur KY. Gallbladder pseudolithiasis caused by ceftriaxone in young adult. J Korean Surg Soc. 2011, 81:423-6. 10.4174\/jkss.2011.81.6.423","journal-title":"J Korean Surg Soc"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt403","article-title":"Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime","volume":"69","author":"Grohs P","year":"2014","unstructured":"Grohs P, Kern\u00e9is S, Sabatier B, et al.. Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother. 2014, 69:786-9. 10.1093\/jac\/dkt403","journal-title":"J Antimicrob Chemother"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1177\/0960327116658108","article-title":"Comparative evaluation of ceftriaxone- and cefotaxime-induced biliary pseudolithiasis or nephrolithiasis: a prospective study in 154 children","volume":"36","author":"Ustyol L","year":"2017","unstructured":"Ustyol L, Bulut MD, Agengin K, et al.. Comparative evaluation of ceftriaxone- and cefotaxime-induced biliary pseudolithiasis or nephrolithiasis: a prospective study in 154 children. Hum Exp Toxicol. 2017, 36:547-53. 10.1177\/0960327116658108","journal-title":"Hum Exp Toxicol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2003.044156","article-title":"Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children","volume":"89","author":"Avci Z","year":"2004","unstructured":"Avci Z, Koktener A, Uras N, et al.. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child. 2004, 89:1069-72. 10.1136\/adc.2003.044156","journal-title":"Arch Dis Child"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/s004310051261","article-title":"Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis","volume":"158","author":"de Moor RA","year":"1999","unstructured":"de Moor RA, Egberts AC, Schr\u00f6der CH. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr. 1999, 158:975-7. 10.1007\/s004310051261","journal-title":"Eur J Pediatr"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/5.11.974","article-title":"Ceftriaxone-associated nephrolithiasis","volume":"5","author":"Cochat P","year":"1990","unstructured":"Cochat P, Cochat N, Jouvenet M, et al.. Ceftriaxone-associated nephrolithiasis. Nephrol Dial Transplant. 1990, 5:974-6. 10.1093\/ndt\/5.11.974","journal-title":"Nephrol Dial Transplant"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-003-0963-0","article-title":"Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child","volume":"33","author":"Prince JS","year":"2003","unstructured":"Prince JS, Senac MO Jr. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Pediatr Radiol. 2003, 33:648-51. 10.1007\/s00247-003-0963-0","journal-title":"Pediatr Radiol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19363","article-title":"Ceftriaxone-associated nephrolithiasis","volume":"34","author":"Grasberger H","year":"2000","unstructured":"Grasberger H, Otto B, Loeschke K. Ceftriaxone-associated nephrolithiasis. Ann Pharmacother. 2000, 34:1076-7. 10.1345\/aph.19363","journal-title":"Ann Pharmacother"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90667-a","article-title":"Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate","volume":"100","author":"Park HZ","year":"1991","unstructured":"Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology. 1991, 100:1665-70. 10.1016\/0016-5085(91)90667-a","journal-title":"Gastroenterology"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2004.05.020","article-title":"Effects of ceftriaxone sodium on in vitro gallbladder contractility in guinea pigs","volume":"122","author":"Arpacik M","year":"2004","unstructured":"Arpacik M, Ceran C, Kaya T, Karadas B, Sarac B, Koyluo\u011flu G. Effects of ceftriaxone sodium on in vitro gallbladder contractility in guinea pigs. J Surg Res. 2004, 122:157-61. 10.1016\/j.jss.2004.05.020","journal-title":"J Surg Res"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90486-k","article-title":"Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility","volume":"99","author":"Shiffman ML","year":"1990","unstructured":"Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterol. 1990, 99:1772-8. 10.1016\/0016-5085(90)90486-k","journal-title":"Gastroenterol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1002\/jcu.20228","article-title":"Ceftriaxone-associated biliary pseudolithiasis in children","volume":"34","author":"Biner B","year":"2006","unstructured":"Biner B, Oner N, Celtik C, Bostancio\u011flu M, Tun\u00e7bilek N, G\u00fczel A, Karasaliho\u011flu S. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound. 2006, 34:217-22. 10.1002\/jcu.20228","journal-title":"J Clin Ultrasound"},{"key":"ref68","article-title":"World Health Organization. WHO Model List of Essential Medicines for Children - 9th List","year":"2023","unstructured":"WHO Model List of Essential Medicines for Children - 9th list, 2023. World Health Organization, Geneva, Switzerland; 2023. https.\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.03.."},{"key":"ref69","article-title":"National Centre for Disease Control. National Treatment Guidelines for Antimicrobial Use in Infectious Diseases. Version 1.0","year":"2016","unstructured":"National Treatment Guidelines for Antimicrobial Use in Infectious Diseases. National Centre for Disease Control, Government of India, New Delhi, India; 2016. https.\/\/ncdc.mohfw.gov.in\/wp-content\/uploads\/2024\/03\/16436207411618303414.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/288340-cefotaxime-versus-ceftriaxone-a-comprehensive-comparative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T03:53:32Z","timestamp":1726026812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/288340-cefotaxime-versus-ceftriaxone-a-comprehensive-comparative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":69,"URL":"https:\/\/doi.org\/10.7759\/cureus.69146","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,11]]}}}